Anixa Biosciences, Inc.

ANIX • Biotechnology

$2.68

▲ +0.07 (+2.68%)

Precio actual

ResultadosÚltimo reporte: 31 jul 2026

PERFIL DÉBILDébilConfianza: 70%

Perfil cuantitativo — no constituye una recomendación de inversión.

Perfil cuantitativo — no constituye una recomendación de inversión.Metodología

Tesis del análisis: Perfil histórico débil. La evidencia actual no sostiene una relación riesgo/retorno favorable.

Capitalización

$91.61M

Crecimiento

-100.0%

Flujo de caja

0/5

Tendencia

Negative

Evidencia

Nivel de deuda manejable · 0.01Liquidez saludable · 8.08Tendencia de crecimiento negativaRentabilidad débil

Datos financieros hasta: 31 jul 2026, 12:00 a.m. UTCÚltima actualización de earnings: 31 jul 2026, 12:00 a.m. UTCÚltima actualización del perfil: 11 sept 2026, 12:10 p.m. UTC

Resumen de la compañía

Valoración, calidad, fortaleza financiera, momentum y datos de analistas.

Price$2.68

Change2.68%

Shares Out34.18M

Market Cap$91.61M

Enterprise Value$77.92M

52W Range2.32 - 5.46

Beta0.60

P/E-11.72

P/B6.33

P/FCF-12.42

EV/EBITDA-7.16

EV/FCF-10.56

Price$2.68

Change2.68%

Shares Out34.18M

Market Cap$91.61M

Enterprise Value$77.92M

52W Range2.32 - 5.46

Beta0.60

P/E-11.72

P/B6.33

P/FCF-12.42

EV/EBITDA-7.16

EV/FCF-10.56

Earnings Yield-8.53%

FCF Yield-8.05%

Dividend Yield0.00%

Gross Margin0.00%

Oper. Margin0.00%

Profit Margin0.00%

Debt/Eq0.01

Current Ratio8.08

Quick Ratio8.08

Revenue 5Y-100.00%

Target$6.00

Target Upside123.88%

Target Median$6.00

Target Range6.00 - 6.00

Volume399.34K

Avg Volume235.09K

EPS Surprise0.03

ADN de inversión

Qué tan fuerte luce esta compañía para inversionistas de largo plazo

de 100

Calidad del negocio

Márgenes, ventaja competitiva, retornos

22/100

Fortaleza financiera

Deuda, caja, estabilidad

76/100

Potencial de crecimiento

Ingresos y expansión

20/100

Atractivo del precio

Barata o cara hoy

30/100

Por qué este puntaje▼

Nivel de deuda manejable · 0.01Liquidez saludable · 8.08Tendencia de crecimiento negativaRentabilidad débil

Analyst view

Analyst sentiment and price target

ANIX

Analyst sentiment

Based on 6 analyst votes · 2026-10-21

100/100

Bullish

Hold

Bearish

Precio objetivo

2026-09-11

Bajo

$3.50

Promedio

$5.83

Mediana

$4.00

Alto

$10.00

Resumen de la compañía

IPO: 10/7/1983

Industria: Biotechnology

P/B i: 6.33

Deuda / Patrimonio i: 0.01

Margen operativo: 0.00%

Margen neto: 0.00%

ROE i: -

ROIC: -

Salud financiera

Puntaje15 / 20

Deuda / Patrimonio: 0.01

Ratio corriente: 8.08

Ratio rápido: 8.08

Estado: Good

Transacciones internas

Actividad reciente de ejecutivos e insiders

KUMAR AMIT

Transacción: 09/10/2026

COMPRA

Cambio

+5,000

Precio

$2.76

Presentación

09/11/2026

Tipo

COMPRA

KUMAR AMIT

Transacción: 07/31/2026

COMPRA

Cambio

+5,000

Precio

$3.47

Presentación

08/03/2026

Tipo

COMPRA

Baskies Arnold M

Transacción: 07/27/2026

VENTA

Cambio

-6,000

Precio

$3.13

Presentación

07/29/2026

Tipo

VENTA

Insider	Tipo	Cambio	Precio	Transacción	Presentación
KUMAR AMIT	COMPRA	+5,000	$2.76	09/10/2026	09/11/2026
KUMAR AMIT	COMPRA	+5,000	$3.47	07/31/2026	08/03/2026
Baskies Arnold M	VENTA	-6,000	$3.13	07/27/2026	07/29/2026
Baskies Arnold M	VENTA	-5,428	$3.46	07/27/2026	07/29/2026
KUMAR AMIT	COMPRA	+5,000	$3.44	07/27/2026	07/28/2026
KUMAR AMIT	COMPRA	+3,188	$3.37	07/27/2026	07/27/2026
KUMAR AMIT	COMPRA	+3,000	$3.73	07/24/2026	07/27/2026
KUMAR AMIT	COMPRA	+5,000	$3.46	07/20/2026	07/21/2026
Titterton Lewis H jr	COMPRA	+12,000	$3.47	07/20/2026	07/20/2026
Titterton Lewis H jr	COMPRA	+2,797	$3.28	07/15/2026	07/16/2026
KUMAR AMIT	COMPRA	+5,000	$3.04	07/10/2026	07/13/2026
Titterton Lewis H jr	COMPRA	+2,836	$2.64	06/16/2026	06/17/2026
KUMAR AMIT	COMPRA	+21,000	$2.50	06/12/2026	06/16/2026
Baskies Arnold M	COMPRA	+10,000	$3.04	01/28/2026	01/29/2026
Baskies Arnold M	COMPRA	+25,000	$3.18	01/05/2026	01/06/2026
Catelani Michael	COMPRA	+175,000	$3.18	01/05/2026	01/06/2026
Gottschalk Emily	COMPRA	+25,000	$3.18	01/05/2026	01/06/2026
KUMAR AMIT	COMPRA	+350,000	$3.18	01/05/2026	01/06/2026
Titterton Lewis H jr	COMPRA	+25,000	$3.18	01/05/2026	01/06/2026
Titterton Lewis H jr	VENTA	-16,000	$2.92	12/15/2025	12/16/2025

Sobre la compañía

Anixa Biosciences, Inc.

Anixa Biosciences, Inc. (ANIX) is a biotechnology company dedicated to pioneering therapies and vaccines. Its core mission revolves around addressing critical, unmet medical needs, particularly within the fields of oncology (cancer) and infectious diseases. Among its therapeutic pipeline, Anixa is developing a novel chimeric endocrine receptor T-cell (CER-T) technology, an innovative adaptation of CAR-T, specifically for ovarian cancer treatment. The company is also engaged in the discovery and development of antiviral drug candidates to combat COVID-19, focusing on the inhibition of specific viral protein functions. On the vaccine front, Anixa's initiatives include a vaccine designed to target triple-negative breast cancer and a distinct preventative vaccine aimed at ovarian cancer. Beyond specific therapies and vaccines, Anixa also has immuno-therapy drugs for various cancers in its development portfolio. A key collaboration exists with MolGenie GmbH for the discovery and development of its COVID-19 antiviral candidates. Tracing its origins back to an incorporation in 1982, the company initially operated as ITUS Corporation before adopting the name Anixa Biosciences, Inc. in October 2018. It is headquartered in San Jose, California.

Fuente - Link

Competidores

ABOS ACTU AGEN ENTX HURA INO IRD SEER SPRO VTGN

Tamaño = capitalización · color = línea del gráfico

Rendimiento de peers · 1A

Top performers + empresa seleccionada

Ultimas Noticias

Anixa Biosciences' Ovarian Cancer CAR-T Therapy Inventor to Deliver Keynote at Ovarian Cancer Midwest Focus Conference

Dr. Jose Conejo-Garcia will speak on immunotherapy for ovarian cancer at the November 2–3 conference SAN JOSE, Calif., Oct. 13, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that Jose Conejo-Garcia, MD, PhD, inventor of Anixa's CAR-T therapy for ovarian cancer, will deliver a keynote presentation at the 2026 Ovarian Cancer Midwest Focus Conference.

PRNewsWire

Anixa Biosciences Announces First Case of Stable Disease for Three Months in Ovarian Cancer CAR-T Clinical Trial

First patient in current dose cohort exhibited no progression of her cancer three months aftertreatment Multiple patients have survived more than one year, including one beyond two years No dose-limiting toxicities observed to date SAN JOSE, Calif., Oct. 5, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that a patient in its ongoing Phase 1, dose-escalating, clinical trial evaluating its novel FSHR-targeted CAR-T therapy for recurrent ovarian cancer, exhibited stable disease 90 days after treatment.

PRNewsWire

Anixa Biosciences Announces Treatment of Second Patient in the Fifth Cohort of its Ovarian Cancer CAR-T Clinical Trial

Multiple Patients Surviving More Than One Year, Including One Beyond Two Years, With No Dose-Limiting Toxicities Observed to Date Patients in Cohort 5 Will Receive 1×10⁷ CAR-Positive Cells/kg Following Lymphodepletion SAN JOSE, Calif., Oct. 1, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the second patient has been treated in the fifth cohort of its ongoing Phase 1, dose-escalating, clinical trial (ClinicalTrials.gov NCT05316129) evaluating its novel FSHR-targeted CAR-T therapy for recurrent ovarian cancer.

PRNewsWire

Anixa Biosciences (NASDAQ:ANIX) Stock: Insider Arnold Baskies Purchases 5,000 Shares

Anixa Biosciences Inc (NASDAQ: ANIX - Get Free Report) Director Arnold Baskies purchased 5,000 shares of the firm's stock in a transaction on Thursday, September 24th. The shares were acquired at an average price of $2.76 per share, with a total value of $13,800.00. Following the purchase, the director directly owned 140,572 shares in the company,

Defense World

Insider Buying: Anixa Biosciences (NASDAQ:ANIX) CEO Buys $19,460.00 in Stock

Anixa Biosciences Inc (NASDAQ: ANIX - Get Free Report) CEO Amit Kumar acquired 7,000 shares of Anixa Biosciences stock in a transaction that occurred on Thursday, September 24th. The shares were bought at an average price of $2.78 per share, with a total value of $19,460.00. Following the transaction, the chief executive officer directly owned 672,000

Defense World

Sorpresas de ganancias

Período	Estimado	Real	Sorpresa
2026-06-10	-0.1	-0.07	0.03
2026-03-09	-0.09	-0.08	0.01
2026-01-12	-0.08797	-0.09	-0.00203
2025-09-10	-0.1	-0.07	0.03
2025-05-28	-0.1	-0.09	0.01
2025-03-11	-0.1	-0.1	0
2025-01-10	-0.11	-0.09	0.02
2024-09-06	-0.11	-0.1	0.01
2024-06-04	-0.11	-0.1	0.01
2024-03-12	-0.09	-0.1	-0.01
2024-01-16	-0.09	-0.09	0
2023-09-06	-0.09	-0.08	0.01